Sign In
Buy CYCC
$6.37
+0 (+0%)
At Close: Dec 10, 2025
Cyclacel Pharmaceuticals To Present Preliminary Data From The Phase 1/2 Clinical Trial Of Oral Fadraciclib At The 34th EORTC-NCI-AACR Symposium
01:15pm, Thursday, 13'th Oct 2022 GlobeNewswire Inc.
- Preliminary Dose Escalation Data to be Presented on Novel CDK2/9 Inhibitor Fadraciclib in Patients with Solid Tumors and Lymphoma - - Preliminary Dose Escalation Data to be Presented on Novel CDK2/9
- Preliminary Dose Escalation Data to be Presented on Novel CDK2/9 Inhibitor Fadraciclib in Patients with Solid Tumors and Lymphoma - - Preliminary Dose Escalation Data to be Presented on Novel CDK2/9
Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2022 Healthcare Conference
01:15pm, Wednesday, 21'st Sep 2022 GlobeNewswire Inc.
BERKELEY HEIGHTS, N.J., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovativ
Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2022 Healthcare Conference
09:15am, Wednesday, 21'st Sep 2022
BERKELEY HEIGHTS, N.J., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative
This Biotechnology Stock Tumbled 37%; Here Are 70 Biggest Movers From Yesterday
07:54am, Friday, 19'th Aug 2022 Benzinga
Gainers
Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares climbed 135.9% to close at $2.17 on Thursday.
Plus Therapeutics, Inc. (NASDAQ: PSTV) shares climbed 53.9% to close at $0.8480
after the co
Why Plus Therapeutics Is Trading Higher By Over 50%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session
04:54pm, Thursday, 18'th Aug 2022 Benzinga
Gainers
Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares jumped 297% to $3.66.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) shares rose 50.9% to $1.1299 amid mention of the stock on Discord. Mind
Penny Stocks To Buy Now? 4 Biotech Stocks To Watch This Week
02:45pm, Thursday, 18'th Aug 2022 PennyStocks
Hot biotech penny stocks to watch thanks to MNMD stock today.
The post Penny Stocks To Buy Now? 4 Biotech Stocks To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information |
Penny Stocks To Buy Now? 4 Biotech Stocks To Watch This Week
10:45am, Thursday, 18'th Aug 2022
Hot biotech penny stocks to watch thanks to MNMD stock today. The post Penny Stocks To Buy Now?
Why FlexShopper Surged Over 47%; Here Are 104 Biggest Movers From Yesterday
08:20am, Friday, 12'th Aug 2022 Benzinga
Gainers
Digital Media Solutions, Inc. (NYSE: DMS) jumped 78.8% to close at $2.11. Digital Media Solutions recently reported worse-than-expected Q2 EPS and sales results.
TOP Financial Group Limited (
Why Matterport Is Trading Higher By Around 25%, Here Are 73 Stocks Moving In Thursday's Mid-Day Session
05:49pm, Thursday, 11'th Aug 2022 Benzinga
Gainers
Timber Pharmaceuticals, Inc. (NYSE: TMBR) shares rose 63.8% to $0.1769. Timber Pharmaceuticals recently announced closing of $8.0 million public offering.
T2 Biosystems, Inc. (NASDAQ: TTOO) s
Why Is Disney Higher By More Than 7%: Here Are 40 Stocks Moving Premarket
11:17am, Thursday, 11'th Aug 2022 Benzinga
Gainers
T2 Biosystems, Inc. (NASDAQ: TTOO) shares rose 44.6% to $0.2284 in pre-market trading. T2 Biosystems shares jumped over 30% on Wednesday after the company on Tuesday announced it will explore
Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q2 2022 Results - Earnings Call Transcript
08:16pm, Wednesday, 10'th Aug 2022
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC ) Q2 2022 Earnings Conference Call August 10, 2022 4:30 PM ET Company Participants Irina Koffler - LifeSci Advisors Spiro Rombotis - President and Chief Exe
Cyclacel Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
08:05pm, Wednesday, 10'th Aug 2022 GlobeNewswire Inc.
- Oral fadraciclib demonstrated good tolerability with continuous dosing; anticipate entering Phase 2 POC stage in 2H 2022 –
Cyclacel: Trading At Less Than Half Its Cash Value, Near-Term Catalysts, No Obvious Bear Thesis
09:53am, Sunday, 07'th Aug 2022
Cyclacel Pharmaceuticals is an oncology company with two major value drivers in Phase 1/2 trials and overdue catalysts. It trades at an $11 million market cap, with last reported cash of $34.5 million
Cyclacel Pharmaceuticals to Release Second Quarter 2022 Financial Results
01:15pm, Wednesday, 03'rd Aug 2022 GlobeNewswire Inc.
BERKELEY HEIGHTS, N.J., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative
